204
Participants
Start Date
June 28, 2021
Primary Completion Date
August 30, 2022
Study Completion Date
September 25, 2024
ARO-ANG3
ARO-ANG3 Injection
Placebo
Sterile Normal Saline (0.9% NaCl)
Paratus Clinical Research, Blacktown
Lakeland Clinical Trials - Rotorua, Rotorua
Lakeland Clinical Trials - Waikato, Hamilton
University of the Sunshine Coast Clinical Trials Centre, Sippy Downs
Linear Clinical Research, Nedlands
NZCR OpCo Ltd., Christchurch
Icahn School of Medicine at Mount Sinai (ISMMS), New York
Capital Area Research, LLC, Camp Hill
Medication Management LLC, Greensboro
Lucas Research, Inc., Morehead City
Progressive Medical Research, Port Orange
AGA Clinical Trials, Hialeah
Global Research Solutions, Miami
Marion Area Health Center, Marion
University of Minnesota, Minneapolis
Methodist Physicians Clinic Heart Consultants, Omaha
Baylor College of Medicine, Houston
Clinical Research of South Nevada, Las Vegas
Velocity Clinical Research, Huntington Park
Lawson Health Research Institute, London
Centre d'Etudes Cliniques, Chicoutimi
Recherche Clinique Sigma Inc, Québec
Ctr de Recherche Clin de Laval, Québec
Lakeland Clinical Trials - Waitemata, Birkenhead
Lead Sponsor
Arrowhead Pharmaceuticals
INDUSTRY